Eyenovia, Inc. (EYEN) has signed a non-binding letter of intent for a potential reverse merger with Betaliq, Inc., a clinical-stage pharmaceutical company focused on glaucoma treatments.
If finalized, the merger would combine Eyenovia's Optejet liquid dispensing platform with Betaliq's EyeSol water-free drug delivery technology, forming a new ophthalmic company with FDA-approved technologies.
The proposed deal values Betaliq at $77 million and Eyenovia at $15 million, with Betaliq shareholders holding 83.7 percent and Eyenovia shareholders 16.3 percent of the combined company. The transaction remains subject to due diligence, definitive agreements, and financing contingencies.
Both companies highlight synergies between EyeSol and Optejet, which could enhance glaucoma treatments and expand ophthalmic product offerings. Eyenovia's Optejet platform is also on track for U.S. regulatory approval in the fourth quarter of 2025.
EYEN is currently trading at $1.43 14.3713% lower on the Nasdaq Capital Market.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.